Effects of XXXX on human eye movements.

@entity3933 @entity3175 @entity1246 @entity146 @entity1245 @entity734 @entity1319
Peak @entity1319 ( @entity1319 ) and average smooth pursuit gain (SP) are reduced in a dose-dependent manner by @entity3175 and provide reliable, quantitative measures of @entity1245 agonist effects. To evaluate the specificity of these eye movement effects for agents acting at the central @entity1246 - @entity1245 receptor complex and the role of sedation in @entity1245 effects, we studied eye movement effects of @entity3933 , a sedating drug which does not act at the @entity1246 - @entity1245 receptor complex. Ten healthy males, aged 19-28 years, with no history of @entity146 or @entity734 , received 50 mg/70 kg intravenous @entity3933 or a similar volume of saline on separate days 1 week apart. @entity1319 , saccade latency and accuracy, SP, self-rated sedation, and short-term memory were assessed at baseline and at 5, 15, 30, 45, 60, 90 and 120 min after drug administration. Compared with placebo, @entity3933 produced significant @entity1319 slowing, and increases in saccade latency and self-rated sedation. There was no significant effect of @entity3933 on smooth pursuit gain, saccade accuracy, or short-term memory. These results suggest that, like @entity3175 , @entity3933 causes sedation, @entity1319 slowing, and an increase in saccade latency. Since the degree of @entity3933 -induced sedation was not correlated with changes in @entity1319 or saccade latency, slowing of saccadic eye movements is unlikely to be attributable to sedation alone. Unlike @entity3175 , @entity3933 does not impair smooth pursuit gain, saccadic accuracy, or memory. Different neurotransmitter systems may influence the neural pathways involved in @entity1319 and smooth pursuit again.
